Neurocrine Biosciences (NBIX) Equity Income (2019 - 2021)
Historic Equity Income for Neurocrine Biosciences (NBIX) over the last 3 years, with Q3 2021 value amounting to -$8.2 million.
- Neurocrine Biosciences' Equity Income fell 1714.29% to -$8.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was -$14.5 million, marking a year-over-year increase of 2520.76%. This contributed to the annual value of -$13.0 million for FY2019, which is N/A changed from last year.
- Latest data reveals that Neurocrine Biosciences reported Equity Income of -$8.2 million as of Q3 2021, which was down 1714.29% from $700000.0 recorded in Q1 2021.
- Neurocrine Biosciences' 5-year Equity Income high stood at $21.0 million for Q2 2019, and its period low was -$28.5 million during Q3 2019.
- In the last 3 years, Neurocrine Biosciences' Equity Income had a median value of -$7.0 million in 2020 and averaged -$3.6 million.
- In the last 5 years, Neurocrine Biosciences' Equity Income crashed by 107058.82% in 2020 and then surged by 10424.24% in 2021.
- Quarter analysis of 3 years shows Neurocrine Biosciences' Equity Income stood at -$7.2 million in 2019, then grew by 2.6% to -$7.0 million in 2020, then decreased by 17.14% to -$8.2 million in 2021.
- Its Equity Income stands at -$8.2 million for Q3 2021, versus $700000.0 for Q1 2021 and -$7.0 million for Q3 2020.